

# Vaccine Basics & Understanding the ACIP Schedule

Training on Immunization Practice Strategies  
(T.I.P.S)

June 24, 2021



# HERD IMMUNITY OR COMMUNITY IMMUNITY

A situation in which a sufficient proportion of a population is immune to an infectious disease (through vaccination and/or prior illness) to make its spread from person to person unlikely. Even individuals not vaccinated (such as newborns and those with chronic illnesses) are offered some protection because the disease has little opportunity to spread within the community.

- CDC Vaccine Glossary



*Herd Immunity Thresholds of vaccine-preventable diseases<sup>6</sup>*

| Disease    | Transmission     | Basic reproduction number | Herd Immunity Threshold |
|------------|------------------|---------------------------|-------------------------|
| Measles    | Airborne         | 12–18                     | 92–95%                  |
| Pertussis  | Airborne droplet | 12–17                     | 92–94%                  |
| Diphtheria | Saliva           | 6–7                       | 83–86%                  |
| Rubella    | Airborne droplet | 6–7                       | 83–86%                  |
| Smallpox   | Airborne droplet | 5–7                       | 80–86%                  |
| Polio      | Fecal-oral route | 5–7                       | 80–86%                  |
| Mumps      | Airborne droplet | 4–7                       | 75–86%                  |
| SARS       | Airborne droplet | 2–5                       | 50–80%                  |
| Ebola      | Bodily fluids    | 1.5–2.5                   | 33–60%                  |
| Influenza  | Airborne droplet | 1.5–1.8                   | 33–44%                  |



# SUMMARY

- We have **room to improve** in Arizona
- **ALL** populations are equally important to immunize!

Use the **chat feature** to tell us your key takeaways!

What do you want to make sure your friends remember?



# You

are the protectors  
of our community's  
immunity.



# **Vaccine PREVENTABLE DISEASES**


- Measles (Rubeola)
- German Measles (Rubella)
- Whooping cough (Pertussis)
- Diphtheria
- Tetanus
- Hepatitis A
- Shingles (Zoster)
- Human papillomavirus (HPV)
- Hepatitis B
- Haemophilus influenza type B (Hib)
- Pneumococcal
- Rotavirus
- Chickenpox (Varicella)
- Influenza (Flu)
- COVID-19
- Polio
- Mumps




**PRIZE!**  
**\$50 GIFT CARD!**



# VACCINES EXPLAINED



BY CHEMAA BOHEMAA  
ILLUSTRATED BY JOYEETA NEOGI





# VACCINE BASICS




# WHY immunize?


Prevent Disease  
Establish Herd Immunity  
Protect the Most Vulnerable




## Trends in Daily COVID-19 Cases and 7-Day Cumulative Incidence Rate of COVID-19 Cases in Arizona Reported to CDC, per 100,000 population




## Trends in Daily COVID-19 Cases and 7-Day Cumulative Incidence Rate of COVID-19 Cases in Arizona Reported to CDC, per 100,000 population



## Trends in Daily COVID-19 Cases and 7-Day Cumulative Incidence Rate of COVID-19 Cases in Arizona Reported to CDC, per 100,000 population





# TYPES OF *immunity*

## HERD

"A situation in which a sufficient proportion of the population (herd) is immune to an infectious disease (through vaccination &/or prior disease) to make its spread from person to person unlikely."



# TYPES OF IMMUNITY

## HERD

"A situation in which a sufficient proportion of the population (herd) is immune to an infectious disease (through vaccination &/or prior disease) to make its spread from person to person unlikely."

## PASSIVE

- Mother to infant
- Blood products
- Immune globulin
- Temporary





# TYPES OF IMMUNITY

## HERD

“A situation in which a sufficient proportion of the population (herd) is immune to an infectious disease (through vaccination &/or prior disease) to make its spread from person to person unlikely.”

## PASSIVE

- Mother to infant
- Blood products
- Immune globulin
- Temporary

## ACTIVE

- Natural disease
- Immunization
- Long-lasting



# VACCINE TYPES

- Inactivated vaccines
- Live-attenuated vaccines
- Messenger RNA (mRNA) vaccines
- Subunit, recombinant, polysaccharide and conjugate vaccines
- Toxoid vaccines
- Viral vector vaccines



- Attenuated (weakened) form of the "wild" virus or bacterium
- Must replicate to be effective
- Immune response similar to natural infection
- Usually produce immunity with one dose\*

\*except those administered orally

**LIVE  
ATTENUATED**



- Attenuated (weakened) form of the "wild" virus or bacterium
- Must replicate to be effective
- Immune response similar to natural infection
- Usually produce immunity with one dose\*

\*except those administered orally

**ROTAVIRUS**

**SMALLPOX**

**MMR**

**YELLOW  
Fever**


**CHICKENPOX**



# INACTIVATED



- Cannot replicate
- Different immune response (humoral)
- Unaffected by antibody in the blood
- Generally require 3-5 doses
- Antibody titer diminishes with time
- Adverse events mostly local with or without fever



# INACTIVATED

- Cannot replicate
- Different immune response (humoral)
- Unaffected by antibody in the blood
- Generally require 3-5 doses
- Antibody titer diminishes with time
- Adverse events mostly local with or without fever

# Messenger RNA



# Messenger RNA

## WIN A PRIZE!

What kinds of questions are you getting about mRNA vaccines?





# **SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE**

- Hib
- Hepatitis B
- HPV
- Whooping cough
- Pneumococcal disease
- Meningococcal disease
- Shingles




# MORE VACCINE TYPES

## **VIRAL VECTOR**

COVID-19

## **TOXOID**

Diphtheria  
Tetanus



# General Rule

The more similar a vaccine is to the disease-causing form of the organism, the better the immune response to the vaccine



# QUIZ

How many  
vaccines can be  
given at one time?



# GENERAL RULE

All vaccines can be administered at the same visit as all other vaccines



# General Rule

- Increasing the interval between doses of a multidose vaccine does **not diminish** the effectiveness of the vaccine.
- Decreasing the interval between doses of a multidose vaccine **may interfere** with antibody response and protection.




# CONTRAINDICATIONS & PRECAUTIONS

## Three permanent contraindications to vaccines:

- Severe allergic reaction to a vaccine component or following a prior dose
- Encephalopathy (brain swelling) without known cause within seven days of administration of a previous dose of DTP, DTaP or Tdap vaccine
- Severe combined immunodeficiency (rotavirus vaccine)

## Two temporary contraindications to *live* vaccines

- Pregnancy
- Immunosuppression



# ACIP

## ADVISORY COMMITTEE on IMMUNIZATION PRACTICES

- Panel of 15 experts
- Develops written recommendations
- Establishes schedule
- Meets 4 times/ year (*well, not in “COVID times”*)
- Does not recommend alternate schedules





# Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

## Vaccines in the Child and Adolescent Immunization Schedule\*

| Vaccines   | Abbreviations                | Trade names   |
|--|------------------------------|---|
| Diphtheria, tetanus, and acellular pertussis vaccine | DTaP                         | Capitace <sup>®</sup><br>Infanrix <sup>®</sup>                      |
| Diphtheria, tetanus vaccine                          | DT                           | AcHiB <sup>®</sup><br>Hiberix <sup>®</sup><br>Pedvaxim <sup>®</sup> |
| Homophilus influenzae type b vaccine                 | Hib (PRP-T)<br>Hib (PRP-OMP) | Havrix <sup>®</sup><br>Vaxna <sup>®</sup>                           |
| Hepatitis A vaccine                                  | HepA                         | Engerix <sup>®</sup><br>Recombivax HB <sup>®</sup>                  |
| Hepatitis B vaccine                                  | HepB                         | Multiple  |
| Human papillomavirus vaccine                         | HPV                          | FluMist <sup>®</sup> Quadrivalent                                   |

## How to use the child/adolescent immunization schedule

- 1 Determine recommended vaccine by age (Table 1)
- 2 Determine recommended interval for catch-up vaccination (Table 2)
- 3 Assess need for additional recommended vaccines by medical condition and other indications (Table 3)
- 4 Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org).

## Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are shaded in gray.

| Vaccine   | Birth                | 1 mo                     | 2 mos                | 4 mos                | 6 mos                | 9 mos | 12 mos | 15 mos | 18 mos | 19-23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13-15 yrs | 16 yrs | 17-18 yrs |
|---|----------------------|--------------------------|----------------------|----------------------|----------------------|-------|--------|--------|--------|-----------|---------|---------|----------|-----------|-----------|--------|-----------|
| Hepatitis B (HepB)  | 1 <sup>st</sup> dose | ← 2 <sup>nd</sup> dose → |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)                |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | See Notes            |       |        |        |        |           |         |         |          |           |           |        |           |
| Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)                  |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | 3 <sup>rd</sup> dose |       |        |        |        |           |         |         |          |           |           |        |           |
| Haemophilus influenzae type b (Hib)                                     |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | See Notes            |       |        |        |        |           |         |         |          |           |           |        |           |
| Pneumococcal conjugate (PCV13)  |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | 3 <sup>rd</sup> dose |       |        |        |        |           |         |         |          |           |           |        |           |
| Inactivated poliovirus (IPV <18 yrs)                                    |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Influenza (IV)  |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Influenza (LAIV4)   |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Measles, mumps, rubella (MMR)   |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Varicella (VAR)   |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Hepatitis A (HepA)  |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Tetanus, diphtheria, acellular pertussis (Tdap >7 yrs)                  |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Human papillomavirus (HPV)  |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Meningococcal (MenACWY-D 10 mos, MenACWY-CRM 2 mos, MenACWY-TT 2 years) |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Meningococcal B   |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |
| Pneumococcal polysaccharide (PPSV23)                                    |                      |                          |                      |                      |                      |       |        |        |        |           |         |         |          |           |           |        |           |

Range of recommended ages for all children  
Range of recommended ages for catch-up immunization  
Range of recommended ages for certain high-risk groups  
Recommended based on shared clinical decision-making or \*can be used in this age group  
No recommendation/not applicable

# Recommended Adult Immunization Schedule for ages 19 years or older

## How to use the adult immunization schedule

- 1 Determine recommended vaccine by age
- 2 Assess need for additional recommended vaccinations by medical condition and other indications (Table 2)
- 3 Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org).

## Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967


## Table 2 Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2021

| Vaccine                   | Pregnancy                  | Immunocompromised (excluding HIV infection) | HIV infection CD4 count | Asplenia, complement deficiencies | End-stage renal disease; or on hemodialysis   | Heart or lung disease, alcoholism <sup>1</sup> | Chronic liver disease | Diabetes | Health care personnel <sup>2</sup> | Men who have sex with men |
|---------------------------|----------------------------|---|-------------------------|-----------------------------------|---|--|-----------------------|----------|------------------------------------|---------------------------|
| IV or RIV4<br>or<br>LAIV4 |                            |   | <200 mm <sup>3</sup>    | ≥200 mm <sup>3</sup>              |   |  |                       |          |                                    |                           |
| Tdap or Td                | 1 dose Tdap each pregnancy | Not Recommended                             |                         |                                   | 1 dose annually   |  |                       |          |                                    |                           |
| MMR                       | Not Recommended*           | Not Recommended                             |                         |                                   | 1 dose Tdap, then Td or Tdap booster every 10 years                                     |  |                       |          |                                    |                           |
| VAR                       | Not Recommended*           | Not Recommended                             |                         |                                   | Precaution  |  |                       |          |                                    |                           |
| RZV                       | Not Recommended*           | Not Recommended                             |                         |                                   | 1 or 2 doses depending on indication  |  |                       |          |                                    |                           |
| HPV                       | Not Recommended*           | 3 doses through age 26 years                |                         |                                   | 2 doses   |  |                       |          |                                    |                           |
| PCV13                     |                            |   |                         |                                   | 2 or 3 doses through age 26 years depending on age at initial vaccination or condition  |  |                       |          |                                    |                           |
| PPSV23                    |                            |   |                         |                                   | 1 dose  |  |                       |          |                                    |                           |
| HepA                      |                            |   |                         |                                   | 1, 2, or 3 doses depending on age and indication  |  |                       |          |                                    |                           |
| HepB                      |                            |   |                         |                                   | 2, 3, or 4 doses depending on indication, see notes for booster recommendations         |  |                       |          |                                    |                           |
| MenACWY                   |                            |   |                         |                                   | 2 or 3 doses depending on vaccine and indication, see notes for booster recommendations |  |                       |          |                                    |                           |
| MenB                      |                            |   |                         |                                   | 1 dose  |  |                       |          |                                    |                           |
| Hib                       | Precaution                 |   |                         |                                   |   |  |                       |          |                                    |                           |

1. Precaution for LAIV4 does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.  
Recommended vaccination for adults who meet age requirement, lack documentation of vaccination or lack evidence of past infection  
Recommended vaccination for adults with an additional risk factor or another indication  
Precaution—vaccination might be indicated if benefits of protection outweigh risk of adverse reaction  
Recommended vaccination based on shared clinical decision-making  
Not recommended/contraindicated—vaccine should not be administered.  
\*Vaccinate after pregnancy.  
No recommendation/Not applicable

# POLL

How often do patients request an  
alternate schedule?



# SCHEDULE OF ACTIVE IMMUNIZATION FOR INFANTS AND CHILDREN

| Age       | Preparation                            |
|-----------|--|
| 1½-2 mo.  | D.P.T.* Poliomylitis vaccine†          |
| 3 mo.     | D.P.T. Poliomylitis vaccine            |
| 4 mo.     | D.P.T. Poliomylitis vaccine            |
| 10-12 mo. | Smallpox vaccine                       |
| 12-18 mo. | D.P.T. Poliomylitis vaccine            |
| 3-4 yr.   | D.P.T. Poliomylitis vaccine            |
| 5-6 yr.   | Smallpox vaccine                       |
| 8 yr.     | D.T. (Adult type) Poliomylitis vaccine |
| 12 yr.    | D.T. (Adult type) Poliomylitis vaccine |
| 16 yr.    | D.T. (Adult type) Poliomylitis vaccine |

\* D.P.T. = Diphtheria, pertussis, tetanus.

† Poliomylitis vaccine for primary immunization of infants may be given as a separate injection or in a commercially prepared quadruple vaccine with D.P.T.

tussis, and tetanus antigens and poliomyelitis vaccine.

There are few contraindications to poliomyelitis vaccination. It may be performed safely at any time of the year, even when poliomyelitis is prevalent. Reactions are extremely rare. The amount of penicillin present in most of the vac-

PEDIATRICS, August 1960



Table 1.—Recommended Schedule for Active Immunization and Tuberculin Testing of Normal Infants and Children\*

| Age          | Immunization or Test                  |
|--------------|---------------------------------------|
| 2-3 Months   | DTP*, type 1 OPV or trivalent OPV     |
| 3-4 Months   | DTP, type 3 OPV or trivalent OPV      |
| 4-5 Months   | DTP, type 2 OPV or trivalent OPV      |
| 9-11 Months  | Tuberculin test                       |
| 12 Months    | Measles vaccine                       |
| 15-18 Months | DTP, trivalent OPV, smallpox          |
| 2 Years      | Tuberculin test                       |
| 3 Years      | DTP, tuberculin test                  |
| 4 Years      | Tuberculin test                       |
| 6 Years      | TD-smallpox vaccine, tuberculin test  |
|              | Trivalent OPV                         |
| 8 Years      | Tuberculin                            |
| 10 Years     | Tuberculin                            |
| 12 Years     | TD, smallpox vaccine, tuberculin test |
| 14 Years     | Tuberculin                            |
| 16 Years     | Tuberculin                            |

\* DTP indicates diphtheria and tetanus toxoids and pertussis vaccine combined; OPV, oral poliovaccine—if trivalent OPV is used, interval should be six weeks or longer; TD, tetanus and diphtheria toxoids, adult type.

—Vol 15, Oct 1967

The recommended immunization schedule by the AAP in the 1966 Red Book. The first measles vaccine was approved in 1963.

TABLE 1. Recommended schedule for active immunization of normal infants and children (See individual ACIP recommendations for details.)

| Recommended age* | Vaccine(s)†    | Comments   |
|------------------|----------------|--|
| 2 mo.            | DTP-1,§ OPV-1¶ | Can be given earlier in areas of high endemicity   |
| 4 mo.            | DTP-2, OPV-2   | 6-wks-2-mo. interval desired between OPV doses to avoid interference                                   |
| 6 mo.            | DTP-3          | An additional dose of OPV at this time is optional for use in areas with a high risk of polio exposure |
| 15 mo.**         | MMR††          |  |
| 18 mo.**         | DTP-4, OPV-3   | Completion of primary series   |
| 4-6 yr.§§        | DTP-5, OPV-4   | Preferably at or before school entry   |
| 14-16 yr.        | Td¶¶           | Repeat every 10 years throughout life  |

\*These recommended ages should not be construed as absolute, i.e. 2 mos. can be 6-10 weeks, etc.

†For all products used, consult manufacturer's package enclosure for instructions for storage, handling, and administration. Immunobiologics prepared by different manufacturers may vary, and those of the same manufacturer may change from time to time. The package insert should be followed for a specific product.

§DTP—Diphtheria and tetanus toxoids and pertussis vaccine.

¶OPV—Oral, attenuated poliovirus vaccine contains poliovirus types 1, 2, and 3.

\*\*Simultaneous administration of MMR, DTP, and OPV is appropriate for patients whose compliance with medical care recommendations cannot be assured.

††MMR—Live measles, mumps, and rubella viruses in a combined vaccine (see text for discussion of single vaccines versus combination).

§§Up to the seventh birthday.

¶¶Td—Adult tetanus toxoid and diphtheria toxoid in combination, which contains the same dose of tetanus toxoid as DTP or DT and a reduced dose of diphtheria toxoid.

1983 childhood immunization schedule



Chat in your questions about the schedule!

**Table 1** Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are shaded in gray.

| Vaccine  | Birth                | 1 mo                     | 2 mos                | 4 mos                | 6 mos                           | 9 mos                    | 12 mos   | 15 mos                   | 18 mos | 19–23 mos | 2–3 yrs | 4–6 yrs                         | 7–10 yrs | 11–12 yrs                      | 13–15 yrs | 16 yrs               | 17–18 yrs |
|--|----------------------|--------------------------|----------------------|----------------------|---------------------------------|--------------------------|--|--------------------------|--------|-----------|---------|---------------------------------|----------|--------------------------------|-----------|----------------------|-----------|
| Hepatitis B (HepB)   | 1 <sup>st</sup> dose | ← 2 <sup>nd</sup> dose → |                      |                      | ← 3 <sup>rd</sup> dose →        |                          |  |                          |        |           |         |                                 |          |                                |           |                      |           |
| Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)                 |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | See Notes                       |                          |  |                          |        |           |         |                                 |          |                                |           |                      |           |
| Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)                   |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | 3 <sup>rd</sup> dose            |                          |  | ← 4 <sup>th</sup> dose → |        |           |         | 5 <sup>th</sup> dose            |          |                                |           |                      |           |
| <i>Haemophilus influenzae</i> type b (Hib)                               |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | See Notes                       |                          | ← 3 <sup>rd</sup> or 4 <sup>th</sup> dose →<br>See Notes |                          |        |           |         |                                 |          |                                |           |                      |           |
| Pneumococcal conjugate (PCV13)   |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | 3 <sup>rd</sup> dose            |                          | ← 4 <sup>th</sup> dose →                                 |                          |        |           |         |                                 |          |                                |           |                      |           |
| Inactivated poliovirus (IPV <18 yrs)                                     |                      |                          | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose | ← 3 <sup>rd</sup> dose →        |                          |  |                          |        |           |         | 4 <sup>th</sup> dose            |          |                                |           |                      |           |
| Influenza (IIV)  |                      |                          |                      |                      | Annual vaccination 1 or 2 doses |                          |  |                          |        |           |         |                                 | or       | Annual vaccination 1 dose only |           |                      |           |
| Influenza (LAIV4)  |                      |                          |                      |                      |                                 |                          |  |                          |        |           |         | Annual vaccination 1 or 2 doses |          | Annual vaccination 1 dose only |           |                      |           |
| Measles, mumps, rubella (MMR)  |                      |                          |                      |                      | See Notes                       | ← 1 <sup>st</sup> dose → |  |                          |        |           |         | 2 <sup>nd</sup> dose            |          |                                |           |                      |           |
| Varicella (VAR)  |                      |                          |                      |                      |                                 | ← 1 <sup>st</sup> dose → |  |                          |        |           |         | 2 <sup>nd</sup> dose            |          |                                |           |                      |           |
| Hepatitis A (HepA)   |                      |                          |                      |                      | See Notes                       | 2-dose series, See Notes |  |                          |        |           |         |                                 |          |                                |           |                      |           |
| Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)                   |                      |                          |                      |                      |                                 |                          |  |                          |        |           |         |                                 |          | Tdap                           |           |                      |           |
| Human papillomavirus (HPV)   |                      |                          |                      |                      |                                 |                          |  |                          |        |           |         |                                 |          | *                              | See Notes |                      |           |
| Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |                      |                          | See Notes            |                      |                                 |                          |  |                          |        |           |         |                                 |          | 1 <sup>st</sup> dose           |           | 2 <sup>nd</sup> dose |           |
| Meningococcal B  |                      |                          |                      |                      |                                 |                          |  |                          |        |           |         |                                 |          |                                |           |                      |           |
| Pneumococcal polysaccharide (PPSV23)                                     |                      |                          |                      |                      |                                 |                          |  |                          |        |           |         |                                 |          |                                |           |                      |           |

Range of recommended ages for all children
Range of recommended ages for catch-up immunization
Range of recommended ages for certain high-risk groups
Recommended based on shared clinical decision-making or  
\*can be used in this age group
No recommendation/not applicable



Chat in your  
questions  
about the  
schedule!

**Table 2** Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 month Behind, United States, 2021

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. **Always use this table in conjunction with Table 1 and the notes that follow.**

| Children age 4 months through 6 years                             |  |  |  |   |                  |
|---|--|--|--|---|------------------|
| Vaccine   | Minimum Age for Dose 1   | Minimum Interval Between Doses   |  |   |                  |
|   |  | Dose 1 to Dose 2   | Dose 2 to Dose 3   | Dose 3 to Dose 4  | Dose 4 to Dose 5 |
| Hepatitis B   | Birth  | 4 weeks  | 8 weeks and at least 16 weeks after first dose.<br>Minimum age for the final dose is 24 weeks.   |   |                  |
| Rotavirus   | 6 weeks<br>Maximum age for first dose is 14 weeks, 6 days.       | 4 weeks  | 4 weeks<br>Maximum age for final dose is 8 months, 0 days.   |   |                  |
| Diphtheria, tetanus, and acellular pertussis                      | 6 weeks  | 4 weeks  | 4 weeks  | 6 months  | 6 months         |
| <i>Haemophilus influenzae</i> type b                              | 6 weeks  | No further doses needed if first dose was administered at age 15 months or older.<br>4 weeks if first dose was administered before the 1 <sup>st</sup> birthday.<br>8 weeks (as final dose) if first dose was administered at age 12 through 14 months.  | No further doses needed if previous dose was administered at age 15 months or older.<br>4 weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown.<br>8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR<br>if current age is 12 through 59 months and first dose was administered before the 1 <sup>st</sup> birthday and second dose was administered at younger than 15 months; OR<br>if both doses were PRP-OMP (PedvaxHIB, Comvax) and were administered before the 1 <sup>st</sup> birthday. | 8 weeks (as final dose)<br>This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 <sup>st</sup> birthday.   |                  |
| Pneumococcal conjugate  | 6 weeks  | No further doses needed for healthy children if first dose was administered at age 24 months or older.<br>4 weeks if first dose was administered before the 1 <sup>st</sup> birthday.<br>8 weeks (as final dose for healthy children) if first dose was administered at the 1 <sup>st</sup> birthday or after. | No further doses needed for healthy children if previous dose was administered at age 24 months or older.<br>4 weeks if current age is younger than 12 months and previous dose was administered at <7 months old.<br>8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR<br>if current age is 12 months or older and at least 1 dose was administered before age 12 months.  | 8 weeks (as final dose)<br>This dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age. |                  |
| Inactivated poliovirus  | 6 weeks  | 4 weeks  | 4 weeks if current age is <4 years.<br>6 months (as final dose) if current age is 4 years or older.  | 6 months (minimum age 4 years for final dose).  |                  |
| Measles, mumps, rubella   | 12 months  | 4 weeks  |  |   |                  |
| Varicella   | 12 months  | 3 months   |  |   |                  |
| Hepatitis A   | 12 months  | 6 months   |  |   |                  |
| Meningococcal ACWY  | 2 months MenACWY-CRM<br>9 months MenACWY-D<br>2 years MenACWY-TT | 8 weeks  | See Notes  | See Notes   |                  |
| Children and adolescents age 7 through 18 years                   |  |  |  |   |                  |
| Meningococcal ACWY  | Not applicable (N/A)   | 8 weeks  |  |   |                  |
| Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis | 7 years  | 4 weeks  | 4 weeks if first dose of DTaP/DT was administered before the 1 <sup>st</sup> birthday.<br>6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 <sup>st</sup> birthday.  | 6 months if first dose of DTaP/DT was administered before the 1 <sup>st</sup> birthday.   |                  |
| Human papillomavirus  | 9 years  | Routine dosing intervals are recommended.  |  |   |                  |
| Hepatitis A   | N/A  | 6 months   |  |   |                  |
| Hepatitis B   | N/A  | 4 weeks  | 8 weeks and at least 16 weeks after first dose.  |   |                  |
| Inactivated poliovirus  | N/A  | 4 weeks  | 6 months<br>A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.   | A fourth dose of IPV is indicated if all previous doses were administered at <4 years or if the third dose was administered <6 months after the second dose.                                      |                  |
| Measles, mumps, rubella   | N/A  | 4 weeks  |  |   |                  |
| Varicella   | N/A  | 3 months if younger than age 13 years.<br>4 weeks if age 13 years or older.  |  |   |                  |

# Minimum AGes/ INTERVALS


## Spacing between vaccine doses

- Minimum age for receiving initial doses
- Minimum intervals between doses
- Grace period of **4 days** for all vaccines includes initial doses and intervals between doses
- If dose of vaccine is given at a **shorter** interval (allowing grace period) even one day shorter - **it doesn't** count as a valid dose
- **Doses too close can reduce vaccine effectiveness**



# POLL

What have you tried that you would  
recommend to others?



**Table 2** Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2021

| Vaccine                           | Pregnancy   | Immuno-compromised (excluding HIV infection)  | HIV infection CD4 count  |  | Asplenia, complement deficiencies | End-stage renal disease; or on hemodialysis | Heart or lung disease, alcoholism <sup>1</sup> | Chronic liver disease | Diabetes               | Health care personnel <sup>2</sup> | Men who have sex with men |
|-----------------------------------|---|---|--|--|-----------------------------------|---|--|-----------------------|------------------------|------------------------------------|---------------------------|
|                                   |   |   | <200 mm <sup>3</sup>   | ≥200 mm <sup>3</sup>                               |                                   |   |  |                       |                        |                                    |                           |
| IIV or RIV4<br><b>or</b><br>LAIV4 | 1 dose annually   |   |  |  |                                   |   |  |                       |                        |                                    |                           |
|                                   | Not Recommended   |   |  |  |                                   | Precaution                                  |  |                       |                        | 1 dose annually<br><b>or</b>       |                           |
| Tdap or Td                        | 1 dose Tdap each pregnancy  | 1 dose Tdap, then Td or Tdap booster every 10 years                                     |  |  |                                   |   |  |                       |                        |                                    |                           |
| MMR                               | Not Recommended*  | Not Recommended   | 1 or 2 doses depending on indication   |  |                                   |   |  |                       |                        |                                    |                           |
| VAR                               | Not Recommended*  | Not Recommended   |  | 2 doses  |                                   |   |  |                       |                        |                                    |                           |
| RZV                               |   |   | 2 doses at age ≥50 years   |  |                                   |   |  |                       |                        |                                    |                           |
| HPV                               | Not Recommended*  | 3 doses through age 26 years  | 2 or 3 doses through age 26 years depending on age at initial vaccination or condition |  |                                   |   |  |                       |                        |                                    |                           |
| PCV13                             |   | 1 dose  |  |  |                                   |   |  |                       |                        |                                    |                           |
| PPSV23                            |   | 1, 2, or 3 doses depending on age and indication  |  |  |                                   |   |  |                       |                        |                                    |                           |
| HepA                              |   |   |  | 2 or 3 doses depending on vaccine                  |                                   |   |  |                       |                        |                                    |                           |
| HepB                              |   |   |  | 2, 3, or 4 doses depending on vaccine or condition |                                   |   |  |                       | <60 years<br>≥60 years |                                    |                           |
| MenACWY                           | 1 or 2 doses depending on indication, see notes for booster recommendations |   |  |  |                                   |   |  |                       |                        |                                    |                           |
| MenB                              | Precaution  | 2 or 3 doses depending on vaccine and indication, see notes for booster recommendations |  |  |                                   |   |  |                       |                        |                                    |                           |
| Hib                               |   | 3 doses HSCT <sup>3</sup> recipients only   |  | 1 dose   |                                   |   |  |                       |                        |                                    |                           |

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended vaccination for adults with an additional risk factor or another indication

Precaution—vaccination might be indicated if benefit of protection outweighs risk of adverse reaction

Recommended vaccination based on shared clinical decision-making

Not recommended/contraindicated—vaccine should not be administered.  
\*Vaccinate after pregnancy.

No recommendation/Not applicable

1. Precaution for LAIV4 does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.





**Table 1** Recommended Adult Immunization Schedule by Age Group, United States, 2021

| Vaccine   | 19–26 years   | 27–49 years         | 50–64 years | ≥65 years |
|---|---|---------------------|-------------|-----------|
| Influenza inactivated (IIV) or Influenza recombinant (RIV4)<br>or<br>Influenza live, attenuated (LAIV4) | 1 dose annually   |                     |             |           |
|   |   | 1 dose annually     |             |           |
| Tetanus, diphtheria, pertussis (Tdap or Td)   | 1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes)             |                     |             |           |
|   | 1 dose Tdap, then Td or Tdap booster every 10 years                                     |                     |             |           |
| Measles, mumps, rubella (MMR)   | 1 or 2 doses depending on indication (if born in 1957 or later)                         |                     |             |           |
| Varicella (VAR)   | 2 doses (if born in 1980 or later)  |                     | 2 doses     |           |
| Zoster recombinant (RZV)  |   |                     | 2 doses     |           |
| Human papillomavirus (HPV)  | 2 or 3 doses depending on age at initial vaccination or condition                       | 27 through 45 years |             |           |
| Pneumococcal conjugate (PCV13)  | 1 dose  |                     |             | 1 dose    |
| Pneumococcal polysaccharide (PPSV23)  | 1 or 2 doses depending on indication  |                     |             | 1 dose    |
| Hepatitis A (HepA)  | 2 or 3 doses depending on vaccine   |                     |             |           |
| Hepatitis B (HepB)  | 2 or 3 doses depending on vaccine   |                     |             |           |
| Meningococcal A, C, W, Y (MenACWY)  | 1 or 2 doses depending on indication, see notes for booster recommendations             |                     |             |           |
| Meningococcal B (MenB)  | 2 or 3 doses depending on vaccine and indication, see notes for booster recommendations |                     |             |           |
|   | 19 through 23 years   |                     |             |           |
| <i>Haemophilus influenzae</i> type b (Hib)  | 1 or 3 doses depending on indication  |                     |             |           |

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended vaccination for adults with an additional risk factor or another indication

Recommended vaccination based on shared clinical decision-making

No recommendation/ Not applicable

## TIPS & TOOLS

- Have a calendar available in each exam room  
*See our TAPI handout!*
- Count weeks between shots
- Check the age of the child to assure accurate time for shots





**Información sobre las vacunas infantiles**

| Nacimiento | 1 Mes | 2 Meses | 4 Meses | 6 Meses          | 12 Meses | 15 Meses | 18 Meses | 19-24 Meses | 2-3 Años | 4-6 Años |
|------------|-------|---------|---------|------------------|----------|----------|----------|-------------|----------|----------|
|            | HepB  |         |         |                  | HepB     |          |          |             |          |          |
|            |       | RV      | RV      | RV <sup>1</sup>  |          |          |          |             |          |          |
|            |       | DtaP    | DtaP    | DtaP             |          |          |          | DtaP        |          |          |
|            |       | Hib     | Hib     | Hib <sup>2</sup> |          |          | Hib      |             |          |          |
|            |       | PCV13   | PCV13   | PCV13            |          |          | PCV13    |             |          |          |
|            |       | Polio   | Polio   | PCV13            |          |          | Polio    |             |          |          |
|            |       |         |         |                  |          |          |          |             |          | Gr       |
|            |       |         |         |                  |          |          |          |             |          | MMR      |
|            |       |         |         |                  |          |          |          |             |          | Varicela |

Los recuadros sombreados indican que la vacuna se administra rutinariamente en los rangos de edades mostrados.

*It's time to bring your child back*

Este programa es recomendado por los Centros para el Control y Prevención de las Enfermedades (Centers for Disease Control and Prevention, CDC) a partir de febrero de 2020. Se aplican las siguientes recomendaciones:

1. Se recomiendan dos dosis aplicadas al menos cuatro semanas separadas entre sí para niños de 6 meses a 8 años de edad quienes están recibiendo por primera vez una vacuna contra la gripe.
2. Si alguien le informara si esta dosis sea necesaria.



## Información sobre las Vacunas Infantiles

- Siguiendo el calendario recomendado es la mejor manera de ayudar al sistema inmunológico de su hijo que trabaje bien.
- Si su hijo está atrasado con sus vacunas, no tiene que empezar de nuevo. Hable con su médico acerca de la programación para ponerse al día.

## ¿SABE?

- Hay vacunas denominadas vacunas combinadas que protegen a su hijo de más de una enfermedad y disminuyen el número de inyecciones administradas en una visita.
- Consolando a su hijo durante las inmunizaciones ayuda que esos momentos pasen mucho más rápido, para su hijo y para usted.
- Las vacunas duelen por un momento, pero una enfermedad puede dañar para toda la vida.

## ABRAZANDO LA INMUNIDAD

- La protección contra enfermedades que una madre pasa a su recién nacido se desvanecerá con tiempo; es por eso que es importante seguir el calendario de vacunas infantiles recomendadas.
- Las vacunas ayudan a estimular el sistema inmunológico de su hijo para protegerlo de 4 enfermedades.
- Hable con su médico acerca de cuáles vacunas su hijo y toda la familia necesitan.



Para obtener más información, hable con su proveedor de atención médica, el departamento local de salud pública o llame/visite:

Línea de ayuda nacional de inmunizaciones del CDC: 1-800-CDC-INFO (1-800-232-4636)

**WhyImmunize.org**

**It's time to bring  
your child back!**

¡Es tiempo de que traiga a su niño!



**It's That Time!**  
*¡Ya es Tiempo!*



**WhyImmunize.org**  
Visit [WhyImmunize.org](http://WhyImmunize.org)

# 2021 Calendar



### Dtap Minimum Intervals

**Dose Minimum Intervals**  
1st, 2nd & 3rd doses 4 week interval  
3rd & 4th 6 month interval (24 weeks)  
5th dose 6 months after 4th

**Hepatitis A & B Minimum Intervals**  
Hep A: 1st & 2nd

**Hep A:** 1st & 2nd dose 6 month interval  
**Hep B:** Make sure there are 8 weeks between the last 2 doses (Combo Vaccine- extra dose is invalid. Count from most recent)

## Rotavirus

**Rotavirus**  
1st dose MUST be before 15 weeks  
2nd dose 4-8 weeks later  
Do NOT give after age 8 months

### Other Intervals

**Flu:** 2 doses of vaccine for kids under 9 if this is first flu season vaccinated- 30 days apart

**Live virus vaccines:** must be given on same day or 28 days apart (MMR, Varicella, FluMist)

MMR: given AFTER 1st birthday

WhyImmunize.org  
602.288.7568  
tapiadmin@tapi.org



# **ASIIS Reminder Recall**



# T.I.P.S. VIRTUAL VACCINE CONVERSATIONS

Training on Immunization  
Practice Strategies (T.I.P.S.)

REGISTER  
NOW!

Plan to attend  
each session  
to be eligible  
for a  
**FREE PRIZE!**

TAPI, in collaboration with the Arizona Department of Health Services Immunization Program, presents free trainings that improve immunization practices in public and private providers' offices. Participants receive valuable information on immunization friendly office practices, vaccine handling, state requirements, how to give shots and the state immunization registry.

## Schedule of Virtual Conversations

Training on Immunization Practice Strategies (T.I.P.S.) is a series of 5 sessions **for medical assistants and vaccine coordinators.**

**Session #1 – Thursday, June 10<sup>th</sup>, 12:00-1:00 PM**

*Why Vaccines are Important: Protecting Herd Immunity*

**Session #2 – Thursday, June 24<sup>th</sup>, 12:00-1:00 PM**

*Vaccine Basics and Understanding the ACIP Schedule*

**Session #3 – Thursday, July 8<sup>th</sup>, 12:00-1:00 PM**

*Protecting the Cold Chain and Preparing for Patients*

**Session #4 – Thursday, July 22<sup>nd</sup>, 12:00-1:00 PM**

*Empowering Patients and Administering Vaccines*

**Session #5 – Thursday, August 5<sup>th</sup>, 12:00-1:00 PM**

*Best Practices for Immunization Delivery in Arizona*

\*Shown in AZ Time

REGISTER NOW! ➔

Register **ONCE** & you can  
attend **ALL SESSIONS!**



**Remember  
THE  
POST-TEST!**



# THANK YOU FOR SAVING LIVES EVERY DAY!

To download slides & view the video recording of today's training, visit:

**[HTTPS://WHYIMMUNIZE.ORG/TAPI-TRAINING/](https://whyimmunize.org/tapi-training/)**

CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, and infographics & images by Freepik

